ArticleFrontiers in oncology2022

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.

Andrea Visentin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.